Search Results - "RUTGEERTS, P"

Laboratory markers in IBD: useful, magic, or unnecessary toys? by Vermeire, S, Van Assche, G, Rutgeerts, P

“…Laboratory markers have been investigated in inflammatory bowel disease (IBD) for diagnostic and differential diagnostic purposes, for assessment of disease…”
Get full text

Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease by Lobatón, T., Ferrante, M., Rutgeerts, P., Ballet, V., Van Assche, G., Vermeire, S.

“…Summary Background The general increased life expectancy is reflected in the age of patients with inflammatory bowel disease (IBD). The knowledge about…”
Get full text

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy by Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.

“…Summary Background In Phase 3 studies of ustekinumab, a fully human monoclonal IL‐12/23p40 antibody approved for moderate‐to‐severe Crohn's disease, patients…”
Get full text

Review article: anti‐adhesion therapies for inflammatory bowel disease by Lobatón, T., Vermeire, S., Assche, G., Rutgeerts, P.

“…Summary Background A high proportion of patients with inflammatory bowel disease (IBD) do not achieve clinical remission with the current therapies including…”
Get full text

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study by Fidder, H, Schnitzler, F, Ferrante, M, Noman, M, Katsanos, K, Segaert, S, Henckaerts, L, Van Assche, G, Vermeire, S, Rutgeerts, P

“…This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. The…”
Get more information

Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience by Danese, S., Colombel, J.‐F., Reinisch, W., Rutgeerts, P. J.

“…Aliment Pharmacol Ther 2011; 33: 857–869 Summary Background  Crohn’s disease is a progressive condition, with most patients developing a penetrating or…”
Get full text

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis by Colombel, J.‐F., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rutgeerts, P., Tang, K. L., Oortwijn, A., Bevelander, G. S., Cornillie, F. J., Sandborn, W. J.

“…Summary Background As treatment goals in Crohn's disease (CD) evolve, targets now include clinical remission (CR), mucosal healing (MH) and biological…”
Get full text

Review article: infliximab therapy for inflammatory bowel disease – seven years on by RUTGEERTS, P., ASSCHE, G., VERMEIRE, S.

“…Summary Infliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and…”
Get full text

Review article: recurrence of Crohn's disease after surgery – the need for treatment of new lesions by RUTGEERTS, P.

“…Summary Crohn's recurrence is the appearance of objective signs – defined radiologically, endoscopically or pathologically – of Crohn's disease in the bowel of…”
Get full text

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis by Arijs, I, Li, K, Toedter, G, Quintens, R, Van Lommel, L, Van Steen, K, Leemans, P, De Hertogh, G, Lemaire, K, Ferrante, M, Schnitzler, F, Thorrez, L, Ma, K, Song, X-Y R, Marano, C, Van Assche, G, Vermeire, S, Geboes, K, Schuit, F, Baribaud, F, Rutgeerts, P

“…Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism…”
Get more information

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease by Vermeire, Severine, Noman, Maja, Van Assche, Gert, Baert, Filip, D’Haens, Geert, Rutgeerts, Paul

“…Background: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to…”
Get full text

Adalimumab for the treatment of fistulas in patients with Crohn's disease by Colombel, J-F, Schwartz, D A, Sandborn, W J, Kamm, M A, D'Haens, G, Rutgeerts, P, Enns, R, Panaccione, R, Schreiber, S, Li, J, Kent, J D, Lomax, K G, Pollack, P F

“…To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn's disease (CD). A phase III, multicentre, randomised,…”
Get more information

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis by Baert, F., Vande Casteele, N., Tops, S., Noman, M., Van Assche, G., Rutgeerts, P., Gils, A., Vermeire, S., Ferrante, M.

“…Summary Background Data for adalimumab in ulcerative colitis after prior use of infliximab are scarce. Aims To study adalimumab response rates and predictors…”
Get full text

Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future by Danese, S., Colombel, J.‐F., Peyrin‐Biroulet, L., Rutgeerts, P., Reinisch, W.

“…Summary Background Until recently, the management of ulcerative colitis (UC) consisted of the stepwise use of mesalazine, corticosteroids and immunomodulators,…”
Get full text

Review article: altering the natural history of Crohn's disease – evidence for and against current therapies by VERMEIRE, S., VAN ASSCHE, G., RUTGEERTS, P.

“…Summary Background The natural course of Crohn's disease is characterized by flare‐ups altered with periods of remission. The majority of Crohn's disease…”
Get full text

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort by Schnitzler, F, Fidder, H, Ferrante, M, Noman, M, Arijs, I, Van Assche, G, Hoffman, I, Van Steen, K, Vermeire, S, Rutgeerts, P

“…This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre…”
Get more information

Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis by Ferrante, M., D'Hoore, A., Vermeire, S., Declerck, S., Noman, M., Van Assche, G., Hoffman, I., Rutgeerts, P., Penninckx, F.

“…Background: Recent reports suggest that the preoperative use of infliximab (IFX) increases postoperative infectious complications in patients with ulcerative…”
Get full text

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? by Rutgeerts, Paul, Vermeire, Severine, Van Assche, Gert

“…The main goal of treatment for Crohn’s disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best…”
Get full text

Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy by Thienpont, C, D'Hoore, A, Vermeire, S, Demedts, I, Bisschops, R, Coremans, G, Rutgeerts, P, Van Assche, G

“…Endoscopic dilatation of Crohn's disease-related strictures is an alternative to surgical resection in selected patients. The influence of disease activity and…”
Get more information

Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy by Bessissow, T., Renard, M., Hoffman, I., Vermeire, S., Rutgeerts, P., Van Assche, G.

“…Summary Background Tumour necrosis factor‐alpha (TNF‐α) is an important mediator of the molecular cascade leading to chronic inflammation. TNF‐α inhibitors…”
Get full text